Compare Cassava Sciences Inc (FLNA) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Logitech International SA — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Logitech International SA trades at $99.71 (market cap $14.35B). The key difference: Logitech International SA is far larger — about 270× Cassava Sciences Inc's market cap, and Logitech International SA pays a 1.7% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LOGI | |
|---|---|---|
Market Cap | $53.14M | $14.35B |
Sector | Health | Technology |
52-Week High | $4.64 | $126.69 |
52-Week Low | $1.09 | $85.84 |
Enterprise Value | -$33.43M | $12.69B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Logitech (LOGI) trades at $100.59, down 1.59% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a 20.81 P/E ratio and robust profitability, including a 14.69% net income margin and 32.78% ROE. Recent earnings beats and a partnership with Call of Duty: Modern Warfare 4 highlight growth momentum, while cash flow trends indicate operational strength despite a slight net outflow in 2025.
The outlook is mixed: analyst consensus targets $113.00 with 26% buy ratings, but technical resistance near $102 poses near-term challenges. Risks include competitive pressures and market volatility, though B2B and AI product expansion offers upside. The stock presents a balanced opportunity for growth-focused investors amid cautious sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
